SecBot SecBot
10-K/A ·Filed Apr 28, 2026

BLFS

BIOLIFE SOLUTIONS INC
NEUTRAL
Impact 2/10
Horizondays Processed6mo ago SEC0001628280-26-028012
Amended annual report (potential restatement)
Actionable Insight • Neutral

This is a purely administrative filing to add proxy-required disclosures. No financial restatement, no material weakness, and no change to the company's reported results. Monitor the next quarterly filing for any updates on the NetSuite MRP implementation (which missed its 2025 target) and for continued revenue growth trajectory.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$19.99
T+0 close · Apr 28, 2026 · via day close
Latest settled
+49.98%
T+60 · $29.98
Vs SPY
+45.86%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 29 $19.99entry
  2. T+1 · 7mo ago +5.45%α +4.43% · $21.08
  3. T+5 · 7mo ago +8.80%α +5.69% · $21.75
  4. T+20 · 6mo ago +26.31%α +20.26% · $25.25
  5. T+60 · 4mo ago +49.98%α +45.86% · $29.98

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioLife Solutions filed Amendment No. 1 to its 2025 10-K solely to add Part III items (directors, executive compensation, security ownership, related transactions, and auditor fees) that were omitted from the original filing because the company will not file a definitive proxy statement within 120 days of year-end. No financial statements were amended or restated, and no errors or material weaknesses were disclosed. The filing is administrative in nature and does not change the company's reported financial position or results.

Key Facts

  • Amendment adds Part III items (10, 11, 12, 13, 14) that were missing from the original 10-K filed February 26, 2026.
  • No financial statements were amended, restated, or revised in this filing.
  • The company filed new CEO and CFO certifications under Rule 13a-14(a) as exhibits.
  • Revenue for FY2025 was $96.2 million, up 29% from $74.6 million in FY2024.
  • GAAP net loss from continuing operations was $12.1 million for FY2025.
  • Adjusted EBITDA was $28.1 million (29% of revenue) for FY2025.
  • No material weaknesses in internal controls were reported for FY2025.
  • CEO Roderick de Greef's total 2025 compensation was $10.47 million.
  • Insider ownership by directors and executive officers totals 1,101,103 shares (2.3% of outstanding).
  • Five institutional holders each own more than 5%: Casdin Capital (12.2%), BlackRock (11.1%), T. Rowe Price (10.6%), Invesco (8.0%), Vanguard (5.3%).

Financial Impact

No financial impact from this amendment. FY2025 revenue of $96.2M, GAAP net loss of $12.1M, adjusted EBITDA of $28.1M.

Risk Factors

  • The NetSuite MRP module implementation was not completed in 2025, resulting in zero payout on that 20% bonus objective.
  • Several late Section 16(a) filings were reported by executives and a 10% holder, indicating potential insider trading compliance gaps.
  • The company reported a GAAP net loss of $12.1M despite strong revenue growth, driven by $15.5M in IPR&D expense and $21.3M in share-based compensation.

Market Snapshot

Exchange
Nasdaq
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
10-K/A Filing (Primary)0001628280-26-028012
Document: blfsfy2025exhibit313.htm0001628280-26-028012
Document: blfsfy2025exhibit314.htm0001628280-26-028012
Document: 0001628280-26-028012-index-headers.html0001628280-26-028012
Document: 0001628280-26-028012-index.html0001628280-26-028012
Document: 0001628280-26-028012.txt0001628280-26-028012

Track record

15 reports on BLFS

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry price pending
  2. Nov 6, 202610d ago Institutional Cluster Bearish 4/10 No price data
  3. Oct 27, 202620d ago SC 13G/A Neutral 3/10 No price data
  4. Oct 16, 20264w ago 15-12G Neutral 4/10 No price data
  5. Oct 13, 20264w ago EFFECT Neutral 3/10 No price data
  6. Oct 13, 20264w ago EFFECT Neutral 3/10 No price data
  7. Oct 6, 20265w ago 8-K Bullish 7/10 Entry $39.00 No price data
  8. Sep 30, 20266w ago 425 Neutral 4/10 Entry $38.85 No price data
  9. Sep 30, 20266w ago DEFA14A Neutral 4/10 Entry $38.85 No price data
  10. Sep 24, 20267w ago SC 13G Neutral 4/10 Entry $38.58 No price data
Showing 10 of 15

US Market Status

Market Closed · Opens Wed (10h 31m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 28, 2026